Fibroblast growth factor 21 in chronic kidney disease.

Biomarkers / metabolism Fibroblast Growth Factor-23 Fibroblast Growth Factors / metabolism Humans Kidney / metabolism Renal Insufficiency, Chronic / metabolism
Chronic kidney disease Diabetic nephropathy FGF21

Journal

Journal of nephrology
ISSN: 1724-6059
Titre abrégé: J Nephrol
Pays: Italy
ID NLM: 9012268

Informations de publication

Date de publication:
Jun 2019
Historique:
received: 06 08 2018
accepted: 15 10 2018
pubmed: 16 11 2018
medline: 15 8 2020
entrez: 16 11 2018
Statut: ppublish

Résumé

Fibroblast growth factor 21 (FGF21) is a member of the endocrine FGF family that acts as a metabolic regulator of both glucose and lipid metabolism. Similar to fibroblast growth factor 23 (FGF23), serum FGF21 levels rise progressively with the loss of renal function, reaching 20 times normal values in end-stage renal disease. In patients with chronic kidney disease (CKD), higher serum FGF21 levels correlate with poorer metabolic profile, higher inflammatory markers, more comorbidities, and higher mortality. The high serum FGF21 levels are above and beyond what can be explained by the loss of FGF21 renal clearance, suggesting increased production and/or impaired non-renal clearance. In diabetic nephropathy, serum FGF21 levels correlate with the severity of albuminuria and faster loss of glomerular filtrate rate and can potentially be a biomarker of poor prognostic. The observational and associative human data contrast sharply with in vitro and in vivo preclinical experimental data, which is more in line with a protective role of FGF21 in chronic nephropathies. We here review the physiology of FGF21, and the literature regarding its behavior in CKD with particular focus on diabetic nephropathy. Finally, we speculate on the role of FGF21 in CKD.

Identifiants

DOI: 10.1007/s40620-018-0550-y PMID: 30430412 PMC: PMC6483847
pubmed: 30430412
doi: 10.1007/s40620-018-0550-y
pii: 10.1007/s40620-018-0550-y
pmc: PMC6483847
mid: NIHMS1021348
doi:

Substances chimiques

Biomarkers 0
FGF23 protein, human 0
fibroblast growth factor 21 0
Fibroblast Growth Factors 62031-54-3
Fibroblast Growth Factor-23 7Q7P4S7RRE

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

365-377

Subventions

Organisme : NIDDK NIH HHS
ID : R01 DK091392
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK092461
Pays : United States
Organisme : Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
ID : 88881.132370/2016-01

Références

Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ, Sandusky GE, Hammond LJ, Moyers JS, Owens RA, Gromada J, Brozinick JT, Hawkins ED, Wroblewski VJ, Li DS, Mehrbod F, Jaskunas SR, Shanafelt AB (2005) FGF-21 as a novel metabolic regulator. J Clin Investig 115(6):1627–1635. https://doi.org/10.1172/jci23606
doi: 10.1172/JCI23606 pubmed: 15902306
Hindricks J, Ebert T, Bachmann A, Kralisch S, Lossner U, Kratzsch J, Stolzenburg JU, Dietel A, Beige J, Anders M, Bast I, Bluher M, Stumvoll M, Fasshauer M (2014) Serum levels of fibroblast growth factor-21 are increased in chronic and acute renal dysfunction. Clin Endocrinol 80(6):918–924. https://doi.org/10.1111/cen.12380
doi: 10.1111/cen.12380
Kohara M, Masuda T, Shiizaki K, Akimoto T, Watanabe Y, Honma S, Sekiguchi C, Miyazawa Y, Kusano E, Kanda Y, Asano Y, Kuro OM, Nagata D (2017) Association between circulating fibroblast growth factor 21 and mortality in end-stage renal disease. PLoS One 12(6):e0178971. https://doi.org/10.1371/journal.pone.0178971
doi: 10.1371/journal.pone.0178971 pubmed: 28582462 pmcid: 5459464
Jian WX, Peng WH, Jin J, Chen XR, Fang WJ, Wang WX, Qin L, Dong Y, Su Q (2012) Association between serum fibroblast growth factor 21 and diabetic nephropathy. Metabolism 61(6):853–859. https://doi.org/10.1016/j.metabol.2011.10.012
doi: 10.1016/j.metabol.2011.10.012 pubmed: 22136913
Lee CH, Hui EY, Woo YC, Yeung CY, Chow WS, Yuen MM, Fong CH, Xu A, Lam KS (2015) Circulating fibroblast growth factor 21 levels predict progressive kidney disease in subjects with type 2 diabetes and normoalbuminuria. J Clin Endocrinol Metab 100(4):1368–1375. https://doi.org/10.1210/jc.2014-3465
doi: 10.1210/jc.2014-3465 pubmed: 25625802
Esteghamati A, Khandan A, Momeni A, Behdadnia A, Ghajar A, Nikdad MS, Noshad S, Nakhjavani M, Afarideh M (2017) Circulating levels of fibroblast growth factor 21 in early-stage diabetic kidney disease. Irish J Med Sci 186(3):785–794. https://doi.org/10.1007/s11845-017-1554-7
doi: 10.1007/s11845-017-1554-7 pubmed: 28181108
Kim HW, Lee JE, Cha JJ, Hyun YY, Kim JE, Lee MH, Song HK, Nam DH, Han JY, Han SY, Han KH, Kang YS, Cha DR (2013) Fibroblast growth factor 21 improves insulin resistance and ameliorates renal injury in db/db mice. Endocrinology 154(9):3366–3376. https://doi.org/10.1210/en.2012-2276
doi: 10.1210/en.2012-2276 pubmed: 23825123
Zhang C, Shao M, Yang H, Chen L, Yu L, Cong W, Tian H, Zhang F, Cheng P, Jin L, Tan Y, Li X, Cai L, Lu X (2013) Attenuation of hyperlipidemia- and diabetes-induced early-stage apoptosis and late-stage renal dysfunction via administration of fibroblast growth factor-21 is associated with suppression of renal inflammation. PLoS One 8(12):e82275. https://doi.org/10.1371/journal.pone.0082275
doi: 10.1371/journal.pone.0082275 pubmed: 24349242 pmcid: 3857822
Li S, Guo X, Zhang T, Wang N, Li J, Xu P, Zhang S, Ren G, Li D (2017) Fibroblast growth factor 21 ameliorates high glucose-induced fibrogenesis in mesangial cells through inhibiting STAT5 signaling pathway. Biomed Pharmacother 93:695–704. https://doi.org/10.1016/j.biopha.2017.06.100
doi: 10.1016/j.biopha.2017.06.100 pubmed: 28692941
Itoh N, Ornitz DM (2011) Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease. J Biochem 149(2):121–130. https://doi.org/10.1093/jb/mvq121
doi: 10.1093/jb/mvq121 pubmed: 20940169
Ornitz DM, Itoh N (2015) The Fibroblast Growth Factor signaling pathway. Wiley Interdiscip Rev Dev Biol 4(3):215–266. https://doi.org/10.1002/wdev.176
doi: 10.1002/wdev.176 pubmed: 25772309 pmcid: 4393358
Goldfarb M, Schoorlemmer J, Williams A, Diwakar S, Wang Q, Huang X, Giza J, Tchetchik D, Kelley K, Vega A, Matthews G, Rossi P, Ornitz DM, D’Angelo E (2007) Fibroblast growth factor homologous factors control neuronal excitability through modulation of voltage-gated sodium channels. Neuron 55(3):449–463. https://doi.org/10.1016/j.neuron.2007.07.006
doi: 10.1016/j.neuron.2007.07.006 pubmed: 17678857 pmcid: 2974323
Nishimura T, Nakatake Y, Konishi M, Itoh N (2000) Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim Biophys Acta 1492(1):203–206
doi: 10.1016/S0167-4781(00)00067-1 pubmed: 10858549
Hsuchou H, Pan W, Kastin AJ (2007) The fasting polypeptide FGF21 can enter brain from blood. Peptides 28(12):2382–2386. https://doi.org/10.1016/j.peptides.2007.10.007
doi: 10.1016/j.peptides.2007.10.007 pubmed: 17996984 pmcid: 2151924
Stein S, Bachmann A, Lossner U, Kratzsch J, Bluher M, Stumvoll M, Fasshauer M (2009) Serum levels of the adipokine FGF21 depend on renal function. Diabetes Care 32(1):126–128. https://doi.org/10.2337/dc08-1054
doi: 10.2337/dc08-1054 pubmed: 18840768 pmcid: 2606845
Mace ML, Gravesen E, Hofman-Bang J, Olgaard K, Lewin E (2015) Key role of the kidney in the regulation of fibroblast growth factor 23. Kidney Int 88(6):1304–1313. https://doi.org/10.1038/ki.2015.231
doi: 10.1038/ki.2015.231 pubmed: 26221757
Dunshee DR, Bainbridge TW, Kljavin NM, Zavala-Solorio J, Schroeder AC, Chan R, Corpuz R, Wong M, Zhou W, Deshmukh G, Ly J, Sutherlin DP, Ernst JA, Sonoda J (2016) Fibroblast activation protein cleaves and inactivates fibroblast growth factor 21. J Biol Chem 291(11):5986–5996. https://doi.org/10.1074/jbc.M115.710582
doi: 10.1074/jbc.M115.710582 pubmed: 26797127 pmcid: 4786731
Coppage AL, Heard KR, DiMare MT, Liu Y, Wu W, Lai JH, Bachovchin WW (2016) Human FGF-21 is a substrate of fibroblast activation protein. PLoS One 11(3):e0151269. https://doi.org/10.1371/journal.pone.0151269
doi: 10.1371/journal.pone.0151269 pubmed: 26962859 pmcid: 4786124
Micanovic R, Raches DW, Dunbar JD, Driver DA, Bina HA, Dickinson CD, Kharitonenkov A (2009) Different roles of N- and C- termini in the functional activity of FGF21. J Cell Physiol 219(2):227–234. https://doi.org/10.1002/jcp.21675
doi: 10.1002/jcp.21675 pubmed: 19117008
Kharitonenkov A, Wroblewski VJ, Koester A, Chen YF, Clutinger CK, Tigno XT, Hansen BC, Shanafelt AB, Etgen GJ (2007) The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 148(2):774–781. https://doi.org/10.1210/en.2006-1168
doi: 10.1210/en.2006-1168 pubmed: 17068132
Adams AC, Cheng CC, Coskun T, Kharitonenkov A (2012) FGF21 requires betaklotho to act in vivo. PLoS One 7(11):e49977. https://doi.org/10.1371/journal.pone.0049977
doi: 10.1371/journal.pone.0049977 pubmed: 23209629 pmcid: 3507945
Goetz R, Mohammadi M (2013) Exploring mechanisms of FGF signalling through the lens of structural biology. Nat Rev Mol Cell Biol 14(3):166–180. https://doi.org/10.1038/nrm3528
doi: 10.1038/nrm3528 pubmed: 23403721 pmcid: 3695728
Goetz R, Beenken A, Ibrahimi OA, Kalinina J, Olsen SK, Eliseenkova AV, Xu C, Neubert TA, Zhang F, Linhardt RJ, Yu X, White KE, Inagaki T, Kliewer SA, Yamamoto M, Kurosu H, Ogawa Y, Kuro-o M, Lanske B, Razzaque MS, Mohammadi M (2007) Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol Cell Biol 27(9):3417–3428. https://doi.org/10.1128/mcb.02249-06
doi: 10.1128/MCB.02249-06 pubmed: 17339340 pmcid: 1899957
Lee S, Choi J, Mohanty J, Sousa LP, Tome F, Pardon E, Steyaert J, Lemmon MA, Lax I, Schlessinger J (2018) Structures of beta-klotho reveal a ‘zip code’-like mechanism for endocrine FGF signalling. Nature 553(7689):501–505. https://doi.org/10.1038/nature25010
doi: 10.1038/nature25010 pubmed: 29342135 pmcid: 6594174
Fisher FM, Maratos-Flier E (2016) Understanding the Physiology of FGF21. Annu Rev Physiol 78:223–241. https://doi.org/10.1146/annurev-physiol-021115-105339
doi: 10.1146/annurev-physiol-021115-105339 pubmed: 26654352
Staiger H, Keuper M, Berti L, Hrabe de Angelis M, Haring HU (2017) Fibroblast growth factor 21-metabolic role in mice and men. Endocr Rev 38(5):468–488. https://doi.org/10.1210/er.2017-00016
doi: 10.1210/er.2017-00016 pubmed: 28938407
Straub L, Wolfrum C (2015) FGF21, energy expenditure and weight loss—how much brown fat do you need? Mol Metab 4(9):605–609. https://doi.org/10.1016/j.molmet.2015.06.008
doi: 10.1016/j.molmet.2015.06.008 pubmed: 26413466 pmcid: 4563019
Fazeli PK, Lun M, Kim SM, Bredella MA, Wright S, Zhang Y, Lee H, Catana C, Klibanski A, Patwari P, Steinhauser ML (2015) FGF21 and the late adaptive response to starvation in humans. J Clin Investig 125(12):4601–4611. https://doi.org/10.1172/jci83349
doi: 10.1172/JCI83349 pubmed: 26529252
Ong KL, Rye KA, O’Connell R, Jenkins AJ, Brown C, Xu A, Sullivan DR, Barter PJ, Keech AC (2012) Long-term fenofibrate therapy increases fibroblast growth factor 21 and retinol-binding protein 4 in subjects with type 2 diabetes. J Clin Endocrinol Metab 97(12):4701–4708. https://doi.org/10.1210/jc.2012-2267
doi: 10.1210/jc.2012-2267 pubmed: 23144467
Kim KH, Lee MS (2015) FGF21 as a mediator of adaptive responses to stress and metabolic benefits of anti-diabetic drugs. J Endocrinol 226(1):R1–R16. https://doi.org/10.1530/joe-15-0160
doi: 10.1530/JOE-15-0160 pubmed: 26116622
Wanders D, Forney LA, Stone KP, Burk DH, Pierse A, Gettys TW (2017) FGF21 mediates the thermogenic and insulin-sensitizing effects of dietary methionine restriction but not its effects on hepatic lipid metabolism. Diabetes 66(4):858–867. https://doi.org/10.2337/db16-1212
doi: 10.2337/db16-1212 pubmed: 28096260 pmcid: 5360300
Hondares E, Iglesias R, Giralt A, Gonzalez FJ, Giralt M, Mampel T, Villarroya F (2011) Thermogenic activation induces FGF21 expression and release in brown adipose tissue. J Biol Chem 286(15):12983–12990. https://doi.org/10.1074/jbc.M110.215889
doi: 10.1074/jbc.M110.215889 pubmed: 21317437 pmcid: 3075644
Tanimura Y, Aoi W, Takanami Y, Kawai Y, Mizushima K, Naito Y, Yoshikawa T (2016) Acute exercise increases fibroblast growth factor 21 in metabolic organs and circulation. Physiol Rep 4 (12). https://doi.org/10.14814/phy2.12828
Suomalainen A (2013) Fibroblast growth factor 21: a novel biomarker for human muscle-manifesting mitochondrial disorders. Expert Opin Med Diagn 7(4):313–317. https://doi.org/10.1517/17530059.2013.812070
doi: 10.1517/17530059.2013.812070 pubmed: 23782039
Ribas F, Villarroya J, Hondares E, Giralt M, Villarroya F (2014) FGF21 expression and release in muscle cells: involvement of MyoD and regulation by mitochondria-driven signalling. Biochem J 463(2):191–199. https://doi.org/10.1042/bj20140403
doi: 10.1042/BJ20140403 pubmed: 25055037
Redondo-Angulo I, Mas-Stachurska A, Sitges M, Tinahones FJ, Giralt M, Villarroya F, Planavila A (2017) Fgf21 is required for cardiac remodeling in pregnancy. Cardiovasc Res 113(13):1574–1584. https://doi.org/10.1093/cvr/cvx088
doi: 10.1093/cvr/cvx088 pubmed: 28472473
Guo Y, Liu Q, Gui Y, Liao C, Xu D (2016) Exercise promotes cardiac-specific fibroblast growth factor 21 expression. Int J Cardiol 203:532–533. https://doi.org/10.1016/j.ijcard.2015.10.231
doi: 10.1016/j.ijcard.2015.10.231 pubmed: 26569358
Brahma MK, Adam RC, Pollak NM, Jaeger D, Zierler KA, Pocher N, Schreiber R, Romauch M, Moustafa T, Eder S, Ruelicke T, Preiss-Landl K, Lass A, Zechner R, Haemmerle G (2014) Fibroblast growth factor 21 is induced upon cardiac stress and alters cardiac lipid homeostasis. J Lipid Res 55(11):2229–2241. https://doi.org/10.1194/jlr.M044784
doi: 10.1194/jlr.M044784 pubmed: 25176985 pmcid: 4617126
Planavila A, Fernandez-Sola J, Villarroya F (2017) Cardiokines as modulators of stress-induced cardiac disorders. Adv Protein Chem Struct Biol 108:227–256. https://doi.org/10.1016/bs.apcsb.2017.01.002
doi: 10.1016/bs.apcsb.2017.01.002 pubmed: 28427562
Liu SQ, Tefft BJ, Roberts DT, Zhang LQ, Ren Y, Li YC, Huang Y, Zhang D, Phillips HR, Wu YH (2012) Cardioprotective proteins upregulated in the liver in response to experimental myocardial ischemia. Am J Physiol Heart Circ Physiol 303(12):H1446–H1458. https://doi.org/10.1152/ajpheart.00362.2012
doi: 10.1152/ajpheart.00362.2012 pubmed: 23064833
Liu SQ, Roberts D, Kharitonenkov A, Zhang B, Hanson SM, Li YC, Zhang LQ, Wu YH (2013) Endocrine protection of ischemic myocardium by FGF21 from the liver and adipose tissue. Sci Rep 3:2767. https://doi.org/10.1038/srep02767
doi: 10.1038/srep02767 pubmed: 24067542 pmcid: 3783882
Salminen A, Kaarniranta K, Kauppinen A (2017) Integrated stress response stimulates FGF21 expression: systemic enhancer of longevity. Cell Signal 40:10–21. https://doi.org/10.1016/j.cellsig.2017.08.009
doi: 10.1016/j.cellsig.2017.08.009 pubmed: 28844867
Luo Y, Ye S, Chen X, Gong F, Lu W, Li X (2017) Rush to the fire: FGF21 extinguishes metabolic stress, metaflammation and tissue damage. Cytokine Growth Factor Rev 38:59–65. https://doi.org/10.1016/j.cytogfr.2017.08.001
doi: 10.1016/j.cytogfr.2017.08.001 pubmed: 28887067
Han SH, Choi SH, Cho BJ, Lee Y, Lim S, Park YJ, Moon MK, Lee HK, Kang SW, Han DS, Kim YB, Jang HC, Park KS (2010) Serum fibroblast growth factor-21 concentration is associated with residual renal function and insulin resistance in end-stage renal disease patients receiving long-term peritoneal dialysis. Metabolism 59(11):1656–1662. https://doi.org/10.1016/j.metabol.2010.03.018
doi: 10.1016/j.metabol.2010.03.018 pubmed: 20423749
Gonzalez E, Diez JJ, Bajo MA, del Peso G, Grande C, Rodriguez O, Diaz-Almiron M, Iglesias P, Selgas R (2016) Fibroblast growth factor 21 (FGF-21) in peritoneal dialysis patients: natural history and metabolic implications. PLoS One 11(3):e0151698. https://doi.org/10.1371/journal.pone.0151698
doi: 10.1371/journal.pone.0151698 pubmed: 26986485 pmcid: 4795603
Reinhard M, Frystyk J, Jespersen B, Randers E, Bibby BM, Ivarsen P (2015) Response of fibroblast growth factor 21 to meal intake and insulin infusion in patients on maintenance haemodialysis. Clin Endocrinol 83(2):187–195. https://doi.org/10.1111/cen.12737
doi: 10.1111/cen.12737
Patrier L, Dupuy A-M, Granger Vallee A, Chalabi L, Morena M, Canaud B, Cristol J (2012) FGF-23 removal is improved by on-line high-efficiency hemodiafiltration compared to conventional high flux hemodialysis. J Nephrol 26:342–349. https://doi.org/10.5301/jn.5000150
doi: 10.5301/jn.5000150 pubmed: 22573526
Chun S, Bamba T, Suyama T, Ishijima T, Fukusaki E, Abe K, Nakai Y (2016) A high phosphorus diet affects lipid metabolism in rat liver: a DNA microarray analysis. PLoS One 11(5):e0155386. https://doi.org/10.1371/journal.pone.0155386
doi: 10.1371/journal.pone.0155386 pubmed: 27187182 pmcid: 4871335
Fisher FM, Chui PC, Antonellis PJ, Bina HA, Kharitonenkov A, Flier JS, Maratos-Flier E (2010) Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes 59(11):2781–2789. https://doi.org/10.2337/db10-0193
doi: 10.2337/db10-0193 pubmed: 20682689 pmcid: 2963536
Diaz-Delfin J, Hondares E, Iglesias R, Giralt M, Caelles C, Villarroya F (2012) TNF-alpha represses beta-Klotho expression and impairs FGF21 action in adipose cells: involvement of JNK1 in the FGF21 pathway. Endocrinology 153(9):4238–4245. https://doi.org/10.1210/en.2012-1193
doi: 10.1210/en.2012-1193 pubmed: 22778214
Liao MT, Sung CC, Hung KC, Wu CC, Lo L, Lu KC (2012) Insulin resistance in patients with chronic kidney disease. J Biomed Biotechnol 2012:691369. https://doi.org/10.1155/2012/691369
doi: 10.1155/2012/691369 pubmed: 22919275 pmcid: 3420350
Koppe L, Pillon NJ, Vella RE, Croze ML, Pelletier CC, Chambert S, Massy Z, Glorieux G, Vanholder R, Dugenet Y, Soula HA, Fouque D, Soulage CO (2013) p-Cresyl sulfate promotes insulin resistance associated with CKD. J Am Soc Nephrol 24(1):88–99. https://doi.org/10.1681/asn.2012050503
doi: 10.1681/ASN.2012050503 pubmed: 23274953
Wang XH, Mitch WE (2014) Mechanisms of muscle wasting in chronic kidney disease. Nat Rev Nephrol 10(9):504–516. https://doi.org/10.1038/nrneph.2014.112
doi: 10.1038/nrneph.2014.112 pubmed: 24981816 pmcid: 4269363
Granata S, Zaza G, Simone S, Villani G, Latorre D, Pontrelli P, Carella M, Schena FP, Grandaliano G, Pertosa G (2009) Mitochondrial dysregulation and oxidative stress in patients with chronic kidney disease. BMC Genom 10:388. https://doi.org/10.1186/1471-2164-10-388
doi: 10.1186/1471-2164-10-388
Yazdi PG, Moradi H, Yang JY, Wang PH, Vaziri ND (2013) Skeletal muscle mitochondrial depletion and dysfunction in chronic kidney disease. Int J Clin Exp Med 6(7):532–539
pubmed: 23936591 pmcid: 3731184
Gamboa JL, Billings FTt, Bojanowski MT, Gilliam LA, Yu C, Roshanravan B, Roberts LJ 2nd, Himmelfarb J, Ikizler TA, Brown NJ (2016) Mitochondrial dysfunction and oxidative stress in patients with chronic kidney disease. Physiol Rep 4 (9). https://doi.org/10.14814/phy2.12780
Sun CY, Cheng ML, Pan HC, Lee JH, Lee CC (2017) Protein-bound uremic toxins impaired mitochondrial dynamics and functions. Oncotarget 8(44):77722–77733. https://doi.org/10.18632/oncotarget.20773
doi: 10.18632/oncotarget.20773 pubmed: 29100420 pmcid: 5652810
Teta D (2012) Adipokines as uremic toxins. J Ren Nutr 22(1):81–85. https://doi.org/10.1053/j.jrn.2011.10.029
doi: 10.1053/j.jrn.2011.10.029 pubmed: 22200420
Alix PM, Guebre-Egziabher F, Soulage CO (2014) Leptin as an uremic toxin: deleterious role of leptin in chronic kidney disease. Biochimie 105:12–21. https://doi.org/10.1016/j.biochi.2014.06.024
doi: 10.1016/j.biochi.2014.06.024 pubmed: 25010649
Tanaka S, Yano S, Sheikh AM, Nagai A, Sugimoto T (2014) Effects of uremic toxin p-cresol on proliferation, apoptosis, differentiation, and glucose uptake in 3T3–L1 cells. Artif Organs 38(7):566–571. https://doi.org/10.1111/aor.12252
doi: 10.1111/aor.12252 pubmed: 24417700
Stockler-Pinto MB, Saldanha JF, Yi D, Mafra D, Fouque D, Soulage CO (2016) The uremic toxin indoxyl sulfate exacerbates reactive oxygen species production and inflammation in 3T3–L1 adipose cells. Free Radic Res 50(3):337–344. https://doi.org/10.3109/10715762.2015.1125996
doi: 10.3109/10715762.2015.1125996 pubmed: 26617268
Roubicek T, Bartlova M, Krajickova J, Haluzikova D, Mraz M, Lacinova Z, Kudla M, Teplan V, Haluzik M (2009) Increased production of proinflammatory cytokines in adipose tissue of patients with end-stage renal disease. Nutrition 25(7–8):762–768. https://doi.org/10.1016/j.nut.2008.12.012
doi: 10.1016/j.nut.2008.12.012 pubmed: 19539174
Xiang DM, Song XZ, Zhou ZM, Liu Y, Dai XY, Huang XL, Hou FF, Zhou QG (2017) Chronic kidney disease promotes chronic inflammation in visceral white adipose tissue. Am J Physiol Renal Physiol 312(4):F689–Ff701. https://doi.org/10.1152/ajprenal.00584.2016
doi: 10.1152/ajprenal.00584.2016 pubmed: 28100503
Huang X, Yu C, Jin C, Yang C, Xie R, Cao D, Wang F, McKeehan WL (2006) Forced expression of hepatocyte-specific fibroblast growth factor 21 delays initiation of chemically induced hepatocarcinogenesis. Mol Carcinog 45(12):934–942. https://doi.org/10.1002/mc.20241
doi: 10.1002/mc.20241 pubmed: 16929488
Owen BM, Bookout AL, Ding X, Lin VY, Atkin SD, Gautron L, Kliewer SA, Mangelsdorf DJ (2013) FGF21 contributes to neuroendocrine control of female reproduction. Nat Med 19(9):1153–1156. https://doi.org/10.1038/nm.3250
doi: 10.1038/nm.3250 pubmed: 23933983 pmcid: 3769455
Wei W, Dutchak PA, Wang X, Ding X, Wang X, Bookout AL, Goetz R, Mohammadi M, Gerard RD, Dechow PC, Mangelsdorf DJ, Kliewer SA, Wan Y (2012) Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor gamma. Proc Natl Acad Sci USA 109(8):3143–3148. https://doi.org/10.1073/pnas.1200797109
doi: 10.1073/pnas.1200797109 pubmed: 22315431
Kubicky RA, Wu S, Kharitonenkov A, De Luca F (2012) Role of fibroblast growth factor 21 (FGF21) in undernutrition-related attenuation of growth in mice. Endocrinology 153(5):2287–2295. https://doi.org/10.1210/en.2011-1909
doi: 10.1210/en.2011-1909 pubmed: 22374976
Badman MK, Koester A, Flier JS, Kharitonenkov A, Maratos-Flier E (2009) Fibroblast growth factor 21-deficient mice demonstrate impaired adaptation to ketosis. Endocrinology 150(11):4931–4940. https://doi.org/10.1210/en.2009-0532
doi: 10.1210/en.2009-0532 pubmed: 19819944 pmcid: 2775979
Johnson CL, Weston JY, Chadi SA, Fazio EN, Huff MW, Kharitonenkov A, Koester A, Pin CL (2009) Fibroblast growth factor 21 reduces the severity of cerulein-induced pancreatitis in mice. Gastroenterology 137(5):1795–1804. https://doi.org/10.1053/j.gastro.2009.07.064
doi: 10.1053/j.gastro.2009.07.064 pubmed: 19664632
Johnson CL, Mehmood R, Laing SW, Stepniak CV, Kharitonenkov A, Pin CL (2014) Silencing of the fibroblast growth factor 21 gene is an underlying cause of acinar cell injury in mice lacking MIST1. Am J Physiol Endocrinol Metab 306(8):E916–E928. https://doi.org/10.1152/ajpendo.00559.2013
doi: 10.1152/ajpendo.00559.2013 pubmed: 24549397
Coate KC, Hernandez G, Thorne CA, Sun S, Le TDV, Vale K, Kliewer SA, Mangelsdorf DJ (2017) FGF21 is an exocrine pancreas secretagogue. Cell Metab 25(2):472–480. https://doi.org/10.1016/j.cmet.2016.12.004
doi: 10.1016/j.cmet.2016.12.004 pubmed: 28089565 pmcid: 5299054
So WY, Cheng Q, Xu A, Lam KS, Leung PS (2015) Loss of fibroblast growth factor 21 action induces insulin resistance, pancreatic islet hyperplasia and dysfunction in mice. Cell Death Dis 6:e1707. https://doi.org/10.1038/cddis.2015.80
doi: 10.1038/cddis.2015.80 pubmed: 25811804 pmcid: 4385948
Singhal G, Fisher FM, Chee MJ, Tan TG, El Ouaamari A, Adams AC, Najarian R, Kulkarni RN, Benoist C, Flier JS, Maratos-Flier E (2016) Fibroblast growth factor 21 (FGF21) protects against high fat diet induced inflammation and islet hyperplasia in pancreas. PLoS One 11(2):e0148252. https://doi.org/10.1371/journal.pone.0148252
doi: 10.1371/journal.pone.0148252 pubmed: 26872145 pmcid: 4752212
Xu J, Lloyd DJ, Hale C, Stanislaus S, Chen M, Sivits G, Vonderfecht S, Hecht R, Li YS, Lindberg RA, Chen JL, Jung DY, Zhang Z, Ko HJ, Kim JK, Veniant MM (2009) Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 58(1):250–259. https://doi.org/10.2337/db08-0392
doi: 10.2337/db08-0392 pubmed: 18840786 pmcid: 2606881
Ye D, Wang Y, Li H, Jia W, Man K, Lo CM, Wang Y, Lam KS, Xu A (2014) Fibroblast growth factor 21 protects against acetaminophen-induced hepatotoxicity by potentiating peroxisome proliferator-activated receptor coactivator protein-1alpha-mediated antioxidant capacity in mice. Hepatology 60(3):977–989. https://doi.org/10.1002/hep.27060
doi: 10.1002/hep.27060 pubmed: 24590984
Fisher FM, Chui PC, Nasser IA, Popov Y, Cunniff JC, Lundasen T, Kharitonenkov A, Schuppan D, Flier JS, Maratos-Flier E (2014) Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets. Gastroenterology 147(5):1073–1083.e1076. https://doi.org/10.1053/j.gastro.2014.07.044
doi: 10.1053/j.gastro.2014.07.044 pubmed: 25083607 pmcid: 4570569
Tanaka N, Takahashi S, Zhang Y, Krausz KW, Smith PB, Patterson AD, Gonzalez FJ (2015) Role of fibroblast growth factor 21 in the early stage of NASH induced by methionine- and choline-deficient diet. Biochim Biophys Acta 1852(7):1242–1252. https://doi.org/10.1016/j.bbadis.2015.02.012
doi: 10.1016/j.bbadis.2015.02.012 pubmed: 25736301 pmcid: 4433820
Kim SH, Kim KH, Kim HK, Kim MJ, Back SH, Konishi M, Itoh N, Lee MS (2015) Fibroblast growth factor 21 participates in adaptation to endoplasmic reticulum stress and attenuates obesity-induced hepatic metabolic stress. Diabetologia 58(4):809–818. https://doi.org/10.1007/s00125-014-3475-6
doi: 10.1007/s00125-014-3475-6 pubmed: 25537833
Liu Y, Zhao C, Xiao J, Liu L, Zhang M, Wang C, Wu G, Zheng MH, Xu LM, Chen YP, Mohammadi M, Chen SY, Cave M, McClain C, Li X, Feng W (2016) Fibroblast growth factor 21 deficiency exacerbates chronic alcohol-induced hepatic steatosis and injury. Sci Rep 6:31026. https://doi.org/10.1038/srep31026
doi: 10.1038/srep31026 pubmed: 27498701 pmcid: 4976373
Desai BN, Singhal G, Watanabe M, Stevanovic D, Lundasen T, Fisher FM, Mather ML, Vardeh HG, Douris N, Adams AC, Nasser IA, FitzGerald GA, Flier JS, Skarke C, Maratos-Flier E (2017) Fibroblast growth factor 21 (FGF21) is robustly induced by ethanol and has a protective role in ethanol associated liver injury. Mol Metab 6(11):1395–1406. https://doi.org/10.1016/j.molmet.2017.08.004
doi: 10.1016/j.molmet.2017.08.004 pubmed: 29107287 pmcid: 5681240
Planavila A, Redondo I, Hondares E, Vinciguerra M, Munts C, Iglesias R, Gabrielli LA, Sitges M, Giralt M, van Bilsen M, Villarroya F (2013) Fibroblast growth factor 21 protects against cardiac hypertrophy in mice. Nat Commun 4:2019. https://doi.org/10.1038/ncomms3019
doi: 10.1038/ncomms3019 pubmed: 23771152
Joki Y, Ohashi K, Yuasa D, Shibata R, Ito M, Matsuo K, Kambara T, Uemura Y, Hayakawa S, Hiramatsu-Ito M, Kanemura N, Ogawa H, Daida H, Murohara T, Ouchi N (2015) FGF21 attenuates pathological myocardial remodeling following myocardial infarction through the adiponectin-dependent mechanism. Biochem Biophys Res Commun 459(1):124–130. https://doi.org/10.1016/j.bbrc.2015.02.081
doi: 10.1016/j.bbrc.2015.02.081 pubmed: 25712519
Patel V, Adya R, Chen J, Ramanjaneya M, Bari MF, Bhudia SK, Hillhouse EW, Tan BK, Randeva HS (2014) Novel insights into the cardio-protective effects of FGF21 in lean and obese rat hearts. PLoS One 9(2):e87102. https://doi.org/10.1371/journal.pone.0087102
doi: 10.1371/journal.pone.0087102 pubmed: 24498293 pmcid: 3911936
Wang S, Wang Y, Zhang Z, Liu Q, Gu J (2017) Cardioprotective effects of fibroblast growth factor 21 against doxorubicin-induced toxicity via the SIRT1/LKB1/AMPK pathway. Cell Death Dis 8(8):e3018. https://doi.org/10.1038/cddis.2017.410
doi: 10.1038/cddis.2017.410 pubmed: 28837153 pmcid: 5596591
Zhang C, Huang Z, Gu J, Yan X, Lu X, Zhou S, Wang S, Shao M, Zhang F, Cheng P, Feng W, Tan Y, Li X (2015) Fibroblast growth factor 21 protects the heart from apoptosis in a diabetic mouse model via extracellular signal-regulated kinase 1/2-dependent signalling pathway. Diabetologia 58(8):1937–1948. https://doi.org/10.1007/s00125-015-3630-8
doi: 10.1007/s00125-015-3630-8 pubmed: 26040473
Yan X, Chen J, Zhang C, Zhou S, Zhang Z, Chen J, Feng W, Li X, Tan Y (2015) FGF21 deletion exacerbates diabetic cardiomyopathy by aggravating cardiac lipid accumulation. J Cell Mol Med 19(7):1557–1568. https://doi.org/10.1111/jcmm.12530
doi: 10.1111/jcmm.12530 pubmed: 25823710 pmcid: 4511354
Yang H, Feng A, Lin S, Yu L, Lin X, Yan X, Lu X, Zhang C (2018) Fibroblast growth factor-21 prevents diabetic cardiomyopathy via AMPK-mediated antioxidation and lipid-lowering effects in the heart. Cell Death Dis 9(2):227. https://doi.org/10.1038/s41419-018-0307-5
doi: 10.1038/s41419-018-0307-5 pubmed: 29445083 pmcid: 5833682
Zhang J, Cheng Y, Gu J, Wang S, Zhou S, Wang Y, Tan Y, Feng W, Fu Y, Mellen N, Cheng R, Ma J, Zhang C, Li Z, Cai L (2016) Fenofibrate increases cardiac autophagy via FGF21/SIRT1 and prevents fibrosis and inflammation in the hearts of Type 1 diabetic mice. Clin Sci (London, England: 1979) 130(8):625–641. https://doi.org/10.1042/cs20150623
doi: 10.1042/CS20150623
Planavila A, Redondo-Angulo I, Ribas F, Garrabou G, Casademont J, Giralt M, Villarroya F (2015) Fibroblast growth factor 21 protects the heart from oxidative stress. Cardiovasc Res 106(1):19–31. https://doi.org/10.1093/cvr/cvu263
doi: 10.1093/cvr/cvu263 pubmed: 25538153
Liang P, Zhong L, Gong L, Wang J, Zhu Y, Liu W, Yang J (2017) Fibroblast growth factor 21 protects rat cardiomyocytes from endoplasmic reticulum stress by promoting the fibroblast growth factor receptor 1-extracellular signalregulated kinase 1/2 signaling pathway. Int J Mol Med 40(5):1477–1485. https://doi.org/10.3892/ijmm.2017.3140
doi: 10.3892/ijmm.2017.3140 pubmed: 28949374 pmcid: 5627875
Zhao L, Wang H, Xie J, Chen Z, Li X, Niu J (2017) Potent long-acting rhFGF21 analog for treatment of diabetic nephropathy in db/db and DIO mice. BMC Biotechnol 17(1):58. https://doi.org/10.1186/s12896-017-0368-z
doi: 10.1186/s12896-017-0368-z pubmed: 28676059 pmcid: 5496364
Cheng Y, Zhang J, Guo W, Li F, Sun W, Chen J, Zhang C, Lu X, Tan Y, Feng W, Fu Y, Liu GC, Xu Z, Cai L (2016) Up-regulation of Nrf2 is involved in FGF21-mediated fenofibrate protection against type 1 diabetic nephropathy. Free Radic Biol Med 93:94–109. https://doi.org/10.1016/j.freeradbiomed.2016.02.002
doi: 10.1016/j.freeradbiomed.2016.02.002 pubmed: 26849944
Li F, Liu Z, Tang C, Cai J, Dong Z (2018) FGF21 is induced in cisplatin nephrotoxicity to protect against kidney tubular cell injury. FASEB J. https://doi.org/10.1096/fj.201701316R
doi: 10.1096/fj.201701316R pubmed: 30592646 pmcid: 6355074
Lin Z, Pan X, Wu F, Ye D, Zhang Y, Wang Y, Jin L, Lian Q, Huang Y, Ding H, Triggle C, Wang K, Li X, Xu A (2015) Fibroblast growth factor 21 prevents atherosclerosis by suppression of hepatic sterol regulatory element-binding protein-2 and induction of adiponectin in mice. Circulation 131(21):1861–1871. https://doi.org/10.1161/circulationaha.115.015308
doi: 10.1161/CIRCULATIONAHA.115.015308 pubmed: 25794851 pmcid: 4444420
Wu X, Qi YF, Chang JR, Lu WW, Zhang JS, Wang SP, Cheng SJ, Zhang M, Fan Q, Lv Y, Zhu H, Xin MK, Lv Y, Liu JH (2015) Possible role of fibroblast growth factor 21 on atherosclerosis via amelioration of endoplasmic reticulum stress-mediated apoptosis in apoE(−/−) mice. Heart Vessels 30(5):657–668. https://doi.org/10.1007/s00380-014-0557-9
doi: 10.1007/s00380-014-0557-9 pubmed: 25092223
Lin XL, He XL, Zeng JF, Zhang H, Zhao Y, Tan JK, Wang Z (2014) FGF21 increases cholesterol efflux by upregulating ABCA1 through the ERK1/2-PPARgamma-LXRalpha pathway in THP1 macrophage-derived foam cells. DNA Cell Biol 33(8):514–521. https://doi.org/10.1089/dna.2013.2290
doi: 10.1089/dna.2013.2290 pubmed: 24735204
Shang W, Yu X, Wang H, Chen T, Fang Y, Yang X, Zhou P, Nie F, Zhou Q, Zhou J (2015) Fibroblast growth factor 21 enhances cholesterol efflux in THP-1 macrophage-derived foam cells. Mol Med Rep 11(1):503–508. https://doi.org/10.3892/mmr.2014.2731
doi: 10.3892/mmr.2014.2731 pubmed: 25334019
Cao F, Wang S, Cao X, Liu X, Fu K, Hao P, Liu J (2017) Fibroblast growth factor 21 attenuates calcification of vascular smooth muscle cells in vitro. J Pharm Pharmacol 69(12):1802–1816. https://doi.org/10.1111/jphp.12826
doi: 10.1111/jphp.12826 pubmed: 28980322
Shi Y, Lu W, Hou Y, Fu K, Gan F, Liu J (2018) Fibroblast growth factor 21 ameliorates vascular calcification by inhibiting osteogenic transition in vitamin D3 plus nicotine-treated rats. Biochem Biophys Res Commun 495(4):2448–2455. https://doi.org/10.1016/j.bbrc.2017.10.115
doi: 10.1016/j.bbrc.2017.10.115 pubmed: 29273504
Zhang S, Yu D, Wang M, Huang T, Wu H, Zhang Y, Zhang T, Wang W, Yin J, Ren G, Li D (2018) FGF21 attenuates pulmonary fibrogenesis through ameliorating oxidative stress in vivo and in vitro. Biomed Pharmacother 103:1516–1525. https://doi.org/10.1016/j.biopha.2018.03.100
doi: 10.1016/j.biopha.2018.03.100 pubmed: 29864937
Feingold KR, Grunfeld C, Heuer JG, Gupta A, Cramer M, Zhang T, Shigenaga JK, Patzek SM, Chan ZW, Moser A, Bina H, Kharitonenkov A (2012) FGF21 is increased by inflammatory stimuli and protects leptin-deficient ob/ob mice from the toxicity of sepsis. Endocrinology 153(6):2689–2700. https://doi.org/10.1210/en.2011-1496
doi: 10.1210/en.2011-1496 pubmed: 22474187 pmcid: 3359613
Wang A, Huen SC, Luan HH, Yu S, Zhang C, Gallezot JD, Booth CJ, Medzhitov R (2016) Opposing effects of fasting metabolism on tissue tolerance in bacterial and viral inflammation. Cell 166(6):1512–1525.e1512. https://doi.org/10.1016/j.cell.2016.07.026
doi: 10.1016/j.cell.2016.07.026 pubmed: 27610573 pmcid: 5555589
Crasto C, Semba RD, Sun K, Ferrucci L (2012) Serum fibroblast growth factor 21 is associated with renal function and chronic kidney disease in community-dwelling adults. J Am Geriatr Soc 60(4):792–793. https://doi.org/10.1111/j.1532-5415.2011.03879.x
doi: 10.1111/j.1532-5415.2011.03879.x pubmed: 22494291 pmcid: 3325515
Ulu SM, Yuksel S, Altuntas A, Kacar E, Ahsen A, Altug A, Celik S, Sezer MT (2014) Associations between serum hepcidin level, FGF-21 level and oxidative stress with arterial stiffness in CAPD patients. Int Urol Nephrol 46(12):2409–2414. https://doi.org/10.1007/s11255-014-0753-7
doi: 10.1007/s11255-014-0753-7 pubmed: 24908281
Lin Z, Zhou Z, Liu Y, Gong Q, Yan X, Xiao J, Wang X, Lin S, Feng W, Li X (2011) Circulating FGF21 levels are progressively increased from the early to end stages of chronic kidney diseases and are associated with renal function in Chinese. PLoS One 6(4):e18398. https://doi.org/10.1371/journal.pone.0018398
doi: 10.1371/journal.pone.0018398 pubmed: 21525989 pmcid: 3078122
Lin YC, Chang YH, Yang SY, Wu KD, Chu TS (2018) Update of pathophysiology and management of diabetic kidney disease. J Formos Med Assoc. https://doi.org/10.1016/j.jfma.2018.02.007
doi: 10.1016/j.jfma.2018.02.007 pubmed: 30581104 pmcid: 6456053
Izquierdo-Lahuerta A, Martinez-Garcia C, Medina-Gomez G (2016) Lipotoxicity as a trigger factor of renal disease. J Nephrol 29(5):603–610. https://doi.org/10.1007/s40620-016-0278-5
doi: 10.1007/s40620-016-0278-5 pubmed: 26956132
Kharitonenkov A, Beals JM, Micanovic R, Strifler BA, Rathnachalam R, Wroblewski VJ, Li S, Koester A, Ford AM, Coskun T, Dunbar JD, Cheng CC, Frye CC, Bumol TF, Moller DE (2013) Rational design of a fibroblast growth factor 21-based clinical candidate, LY2405319. PLoS One 8(3):e58575. https://doi.org/10.1371/journal.pone.0058575
doi: 10.1371/journal.pone.0058575 pubmed: 23536797 pmcid: 3594191
Gaich G, Chien JY, Fu H, Glass LC, Deeg MA, Holland WL, Kharitonenkov A, Bumol T, Schilske HK, Moller DE (2013) The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab 18(3):333–340. https://doi.org/10.1016/j.cmet.2013.08.005
doi: 10.1016/j.cmet.2013.08.005 pubmed: 24011069
Talukdar S, Zhou Y, Li D, Rossulek M, Dong J, Somayaji V, Weng Y, Clark R, Lanba A, Owen BM, Brenner MB, Trimmer JK, Gropp KE, Chabot JR, Erion DM, Rolph TP, Goodwin B, Calle RA (2016) A long-acting FGF21 molecule, PF-05231023, decreases body weight and improves lipid profile in non-human primates and type 2 diabetic subjects. Cell Metab 23(3):427–440. https://doi.org/10.1016/j.cmet.2016.02.001
doi: 10.1016/j.cmet.2016.02.001 pubmed: 26959184
Kim AM, Somayaji VR, Dong JQ, Rolph TP, Weng Y, Chabot JR, Gropp KE, Talukdar S, Calle RA (2017) Once-weekly administration of a long-acting fibroblast growth factor 21 analogue modulates lipids, bone turnover markers, blood pressure and body weight differently in obese people with hypertriglyceridaemia and in non-human primates. Diabetes Obes Metab 19(12):1762–1772. https://doi.org/10.1111/dom.13023
doi: 10.1111/dom.13023 pubmed: 28573777
Mericq V, De Luca F, Hernandez MI, Pena V, Rossel K, Garcia M, Avila A, Cavada G, Iniguez G (2014) Serum fibroblast growth factor 21 levels are inversely associated with growth rates in infancy. Horm Res Paediatr 82(5):324–331. https://doi.org/10.1159/000367922
doi: 10.1159/000367922 pubmed: 25300595

Auteurs

Paulo Giovanni de Albuquerque Suassuna (PGA)

Laboratory of Experimental Nephrology (LABNEX) and Interdisciplinary Nucleus of Laboratory Animal Studies (NIDEAL), Federal University of Juiz de Fora (UFJF), Rua José Lourenço Kelmer, S/n, Martelos, Juiz de Fora, MG, 36036-330, Brazil. paulosuassuna@gmail.com.
Interdisciplinary Center for Studies, Research and Treatment in Nephrology (NIEPEN), Federal University of Juiz de Fora, Juiz de Fora, Minas Gerais, Brazil. paulosuassuna@gmail.com.
Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA. paulosuassuna@gmail.com.
ORCID: 0000-0002-9123-9564

Rogério Baumgratz de Paula (RB)

Laboratory of Experimental Nephrology (LABNEX) and Interdisciplinary Nucleus of Laboratory Animal Studies (NIDEAL), Federal University of Juiz de Fora (UFJF), Rua José Lourenço Kelmer, S/n, Martelos, Juiz de Fora, MG, 36036-330, Brazil.
Interdisciplinary Center for Studies, Research and Treatment in Nephrology (NIEPEN), Federal University of Juiz de Fora, Juiz de Fora, Minas Gerais, Brazil.

Hélady Sanders-Pinheiro (H)

Laboratory of Experimental Nephrology (LABNEX) and Interdisciplinary Nucleus of Laboratory Animal Studies (NIDEAL), Federal University of Juiz de Fora (UFJF), Rua José Lourenço Kelmer, S/n, Martelos, Juiz de Fora, MG, 36036-330, Brazil.
Interdisciplinary Center for Studies, Research and Treatment in Nephrology (NIEPEN), Federal University of Juiz de Fora, Juiz de Fora, Minas Gerais, Brazil.

Orson W Moe (OW)

Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Department of Physiology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Charles and Jane Pak Center of Mineral Metabolism and Clinical Research, University of Texas Southwestern Medical Center, Dallas, TX, USA.

Ming-Chang Hu (MC)

Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Charles and Jane Pak Center of Mineral Metabolism and Clinical Research, University of Texas Southwestern Medical Center, Dallas, TX, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Fibroblast growth factor 21 in chronic kidney disease.
questionsmedicales.fr › Acides aminés, peptides et protéines › Peptides › Facteur-23 de croissance des fibroblastes › Fibroblast growth factor 21 in chronic kidney disease.
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Facteurs de croissance fibroblastique › Fibroblast growth factor 21 in chronic kidney disease.
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Fibroblast growth factor 21 in chronic kidney disease.
questionsmedicales.fr › Appareil urogénital › Voies urinaires › Rein › Fibroblast growth factor 21 in chronic kidney disease.
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Maladie chronique › Insuffisance rénale chronique › Fibroblast growth factor 21 in chronic kidney disease.